Respiratory Disease Testing Market, By Test Type (Imaging Test, Spirometry, Peak Flow Test, Blood Gas Test, Lung Volume Test, Others), By End User (Hospitals, Physician Offices, Clinical Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023

Code : CMI4030

Pages :178

Formats :

Excel and PDF

Industry : Medical Devices

Regional Analysis

Global Respiratory Disease Testing Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global respiratory disease testing market over the forecast period. North America is estimated to hold 38.3% of the market share North America holds a significant market share in the respiratory disease testing market worldwide, mainly due to the key market players are focusing on inorganic strategies such as merger and increased manufacturing of inhaled antibiotics. For instance, EnBiotix, Inc., a rare disease company focused on chronic respiratory disorders in the U.S., announced the closing of an US$11M pre-merger, convertible note round of financing comprised of Vectura Group plc, the Cystic Fibrosis Foundation, and Sanford Biosciences LLC is developing medicines for unmet patient needs and responding to the demand for increased access to biologic treatments. Thus, North America is also projected to spur the global inhaled antibiotics market growth over the forecast period.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa